Patent · US Active

Compounds

US10858367B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

GlaxoSmithKline Intellectual Property Development Limited · GB

Inventors

Xiao Ding · Chesterfield, US
Feng Ren · Shanghai, CN
Yingxia Sang · Shanghai, CN
Weiqiang XING · Shanghai, CN
Yang Zhan · Shanghai, CN
Baowei Zhao · Shanghai, CN

Key dates

Filing date	Jan 23, 2018
Grant date	Dec 8, 2020
Priority date	—
Expiry date	Jan 23, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/08
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.